Dr Reddy's Laboratories stated that it would launch antiviral drug molnupiravir at a price of Rs 35 per capsule, under the brand name Molflu across India.
The total course of 40 capsules over 5 days would cost Rs 1,400 with 10 capsules per strip.
The company said that it has received emergency-use authorisation from the Drugs Controller General of India (DCGI) to manufacture and market the oral anti-viral drug Molnupiravir capsules 200mg for the treatment of adult patients with COVID-19, with SpO2 >93 per cent and who have high risk of progression of the disease including hospitalisation or death.
Earlier this year, Dr. Reddy’s entered into a non-exclusive voluntary licensing agreement with Merck Sharpe Dohme (MSD) to manufacture and supply Molnupiravir to India and over 100 low and middle-income countries (LMICs).
(With inputs from agencies)
